Genentech to buy Regor’s CDK inhibitors

Roche’s Genentech subsidiary has agreed to pay the biotechnology firm Regor Pharmaceuticals $850 million, plus possible milestone payments, for a portfolio of CDK inhibitors for treating breast cancer. Genentech will be responsible for clinical development, manufacturing, and commercialization; Regor will manage the two ongoing Phase 1 trials.

Authors

Publication Details

Journal
C&EN Global Enterprise
Published
2024-10-07
DOI
https://doi.org/10.1021/cen-10231-buscon16
Primary Topic
Cancer-related Molecular Pathways
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Genentech to buy Regor’s CDK inhibitors

Laura Howes
C&EN Global Enterprise
Cancer-related Molecular Pathways
article

Genentech to buy Regor’s CDK inhibitors

Laura Howes
article en

Abstract

Roche’s Genentech subsidiary has agreed to pay the biotechnology firm Regor Pharmaceuticals $850 million, plus possible milestone payments, for a portfolio of CDK inhibitors for treating breast cancer. Genentech will be responsible for clinical development, manufacturing, and commercialization; Regor will manage the two ongoing Phase 1 trials.

C&EN Global EnterpriseVol. 102(31)
Zero hunger
Openalex Percentile: Top 69%
Cancer-related Molecular Pathways
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Genentech to buy Regor’s CDK inhibitors — Laura Howes · C&EN Global Enterprise (2024) | TGRS Research Map | TGRS